About: Complement inhibition by soluble complement receptor type 1 fails to moderate cerulein-induced pancreatitis in the rat

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Complement inhibition by soluble complement receptor type 1 fails to moderate cerulein-induced pancreatitis in the rat Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Complement inhibition by soluble complement receptor type 1 fails to moderate cerulein-induced pancreatitis in the rat
Creator	Gibbs, Simon Hechtman, Herbert Moore, Francis Weiser, Martin
source	PMC
abstract	CONCLUSION: Cerulein-induced pancreatitis in rats associated with remote liver and lung dysfunction. Soluble complement receptor 1 (sCR1) does not reduce the local or remote injury. Thus complement activation does not moderate cerulein-induced pancreatitis or the associated liver and lung injury. BACKGROUND: The local and remote injury of pancreatitis resembles other inflammatory events that are mediated by complement. This study examines the effect of complement inhibition with sCR1 in cerulein-induced pancreatitis in rats. METHODS: Thirteen Sprague-Dawley rats received five hourly subcutaneous doses of cerulein (100 μg initially, then 50 μg/kg). Six of these animals received hourly iv sCR1 (15 mg/kg, a proven complement-inhibiting dose in rats) and the other seven received iv saline. In parallel, 12 additional rats received hourly sc and iv saline. RESULTS: Compared to saline controls, rats receiving cerulein showed increased pancreatic wet-to-dry ratio (3.25∶8.52) hematocrit (40 to 47%), ascites volume (2.1 to 6.1 mL), serum amylase (1680 to 10,700 U/L), and ascites amylase (32,200 to 167,000 U/L) (allp<0.05). None of these parameters were modified by treatment with sCR1. Serum SGPT, which increased from 33.4 to 46.6 U/L in cerulein-infused rats, showed a trend toward reduction to 38.8 U/L in rats treated with sCR1. Cerulein-treated rats also had increased lung myeloperoxidase (0.069 to 0.097 U/g) and lung permeability, as assessed by alveolar lavage to serum ratio of labeled albumen (0.041∶0.121) (bothp<0.05). Neither were changed by sCR1 treatment.
has issue date	1996-01-01(xsd:dateTime)
bibo:doi	10.1007/bf02805226
bibo:pmid	8723555
has license	no-cc
sha1sum (hex)	a89d859a3e5be2be2c3cf845e83f383694fb8663
schema:url	https://doi.org/10.1007/bf02805226
resource representing a document's title	Complement inhibition by soluble complement receptor type 1 fails to moderate cerulein-induced pancreatitis in the rat
has PubMed Central identifier	PMC7101985
has PubMed identifier	8723555
schema:publication	Int J Gastrointest Cancer
resource representing a document's body	covid:a89d859a3e5be2be2c3cf845e83f383694fb8663#body_text
is schema:about of	named entity 'Pancreatitis' named entity 'lung injury' named entity 'complement receptor 1' named entity 'Soluble' named entity 'Soluble' named entity 'Complement' named entity 'Rat' named entity 'Type 1' named entity 'neutrophil' named entity 'significant difference' named entity 'complement pathways' named entity 'type 1' named entity 'necrotizing' named entity 'necrosis' named entity 'C3a' named entity 'minor role' named entity 'liver injury' named entity 'assay' named entity 'pancreatitis' named entity 'morphologically similar' named entity '0.9' named entity 'oxidation' named entity 'complement receptor' named entity 'neutrophil' named entity 'gastric acid' named entity 'neutrophil' named entity 'lung' named entity 'fat necrosis' named entity 'adult respiratory distress syndrome' named entity 'complement activation' named entity 'lung' named entity 'intravital microscopy' named entity 'venom' named entity 'rodent' named entity 'centrifuged' named entity 'lung' named entity 'pancreas' named entity 'homogenized' named entity 'trachea' named entity 'normal saline' named entity 'small bowel' named entity 'pancreatitis' named entity 'Lung' named entity 'pathogenesis' named entity 'pancreas' named entity 'albumen' named entity 'Sprague-Dawley' named entity 'complement pathways' named entity 'Anesthesia' named entity 'albumin' named entity 'Charles River Laboratories' named entity 'SGPT' named entity 'sonicated' named entity 'C5a' named entity 'CR1' named entity 'lung' named entity 'FITC' named entity 'spectrophotometrically' named entity 'edema' named entity 'enzyme' named entity 'neutrophil' named entity 'vacuoles' named entity 'reflux' named entity 'Animals were treated' named entity 'virus' named entity 'analog' named entity 'hepatic failure' named entity 'analog' named entity 'Complement activation' named entity 'anaphylatoxins' named entity 'hemoconcentration' named entity 'left lung' named entity 'pancreatitis' named entity 'edema' named entity 'CH50' named entity 'serum' named entity 'ascites' named entity 'FITC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software